# Exelixis, Inc.  Share Price Target ‘$26.74’, now 12.8% Upside Potential

- Link: https://www.directorstalkinterviews.com/exelixis-inc.share-price-target-26.74-now-12.8-upside-potential/4121148636
- Published: 2024-03-22T14:04:38+00:00
- Author: Charlotte Edwards

**Exelixis, Inc.** which can be found using ticker (EXEL) now have 19 market analysts
covering the stock. The analyst consensus now points to a rating of ‘buy’. The target
price High/Low ranges between $32.00 and $18.00 calculating the mean target share
price we have $26.74. (at the time of writing). Given that the stocks previous close
was at $23.71 and the analysts are correct then there would likely be a percentage
uptick in value of 12.8%. The 50 day MA is $21.94 while the 200 day moving average
is $21.35. The market capitalization for the company is 7.25B. The stock price for
the company is currently $23.92 USD

 The potential market cap would be $8,179,214,653 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 36.8, revenue per share of $5.75
and a 3.55% return on assets.

Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines
and combination regimens at the forefront of cancer care. It has four products, 
including its flagship molecule, cabozantinib, which is an inhibitor of multiple
tyrosine kinases, including MET, AXL, VEGF receptors and RET. Cabozantinib is approved
as CABOMETYX tablets used for advanced renal cell carcinoma (RCC), both alone and
in combination with Bristol-Myers Squibb Company’s (BMS) OPDIVO (nivolumab), for
hepatocellular carcinoma (HCC) and for radioactive iodine (RAI)-refractory differentiated
thyroid cancer (DTC). Cabozantinib is also approved as COMETRIQ capsules for metastatic
medullary thyroid cancer (MTC). Its other two products are COTELLIC, an inhibitor
of MEK approved as part of multiple combination regimens to treat specific forms
of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the
mineralocorticoid receptor (MR) approved the treatment of hypertension.

Share on: